U.S. markets closed
  • S&P Futures

    3,761.50
    -4.00 (-0.11%)
     
  • Dow Futures

    30,849.00
    -29.00 (-0.09%)
     
  • Nasdaq Futures

    12,426.00
    -29.00 (-0.23%)
     
  • Russell 2000 Futures

    2,140.60
    -3.90 (-0.18%)
     
  • Crude Oil

    64.34
    +0.51 (+0.80%)
     
  • Gold

    1,690.20
    -10.50 (-0.62%)
     
  • Silver

    25.26
    -0.20 (-0.79%)
     
  • EUR/USD

    1.1962
    -0.0017 (-0.14%)
     
  • 10-Yr Bond

    1.5500
    +0.0800 (+5.44%)
     
  • Vix

    28.57
    +1.90 (+7.12%)
     
  • GBP/USD

    1.3895
    +0.0001 (+0.01%)
     
  • USD/JPY

    108.0120
    +0.0360 (+0.03%)
     
  • BTC-USD

    47,229.42
    -3,762.07 (-7.38%)
     
  • CMC Crypto 200

    944.26
    -42.95 (-4.35%)
     
  • FTSE 100

    6,650.88
    -24.59 (-0.37%)
     
  • Nikkei 225

    28,683.85
    -246.26 (-0.85%)
     

Independent Director Briggs Morrison Just Bought A Handful Of Shares In Codiak BioSciences, Inc. (NASDAQ:CDAK)

  • Oops!
    Something went wrong.
    Please try again later.
Simply Wall St
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.

Whilst it may not be a huge deal, we thought it was good to see that the Codiak BioSciences, Inc. (NASDAQ:CDAK) Independent Director, Briggs Morrison, recently bought US$100k worth of stock, for US$21.00 per share. Nevertheless, it only increased their shareholding by a minuscule percentage, and it wasn't a massive purchase by absolute value, either.

Check out our latest analysis for Codiak BioSciences

Codiak BioSciences Insider Transactions Over The Last Year

In fact, the recent purchase by Briggs Morrison was the biggest purchase of Codiak BioSciences shares made by an insider individual in the last twelve months, according to our records. That means that even when the share price was higher than US$19.56 (the recent price), an insider wanted to purchase shares. It's very possible they regret the purchase, but it's more likely they are bullish about the company. In our view, the price an insider pays for shares is very important. Generally speaking, it catches our eye when an insider has purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price. The only individual insider to buy over the last year was Briggs Morrison.

You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

insider-trading-volume
insider-trading-volume

There are always plenty of stocks that insiders are buying. So if that suits your style you could check each stock one by one or you could take a look at this free list of companies. (Hint: insiders have been buying them).

Insider Ownership of Codiak BioSciences

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. We usually like to see fairly high levels of insider ownership. Codiak BioSciences insiders own about US$29m worth of shares. That equates to 6.9% of the company. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.

What Might The Insider Transactions At Codiak BioSciences Tell Us?

It is good to see the recent insider purchase. We also take confidence from the longer term picture of insider transactions. But on the other hand, the company made a loss during the last year, which makes us a little cautious. When combined with notable insider ownership, these factors suggest Codiak BioSciences insiders are well aligned, and that they may think the share price is too low. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. When we did our research, we found 6 warning signs for Codiak BioSciences (3 shouldn't be ignored!) that we believe deserve your full attention.

But note: Codiak BioSciences may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.